Holen Sie sich die Stockscreener-App
1.12
0.90%
0.01
Schlusskurs vom Vortag:
$1.11
Offen:
$1.1
24-Stunden-Volumen:
54,244
Relative Volume:
0.32
Marktkapitalisierung:
$25.07M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-61.06M
KGV:
-0.0782
EPS:
-14.3261
Netto-Cashflow:
$-59.30M
1W Leistung:
-5.08%
1M Leistung:
-5.88%
6M Leistung:
-49.09%
1J Leistung:
-61.11%
1-Tages-Spanne:
$1.09
$1.15
1-Wochen-Bereich:
$1.0501
$1.19
52-Wochen-Spanne:
$1.00
$4.72
Boundless Bio Inc Stock (BOLD) Company Profile
Firmenname
Boundless Bio Inc
Sektor
Branche
Telefon
(858) 766-9912
Adresse
10955 ALEXANDRIA WAY, SAN DIEGO
Vergleichen Sie BOLD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BOLD
Boundless Bio Inc
|
1.12 | 24.85M | 0 | -61.06M | -59.30M | -14.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Boundless Bio Inc Stock (BOLD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-05-28 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-12-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-04-22 | Eingeleitet | Guggenheim | Buy |
| 2024-04-22 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-22 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Boundless Bio Inc Aktie (BOLD) Neueste Nachrichten
Is Boundless Bio Inc. reversing from oversold territory [Weekly Stock Analysis]Stepwise Swing Trade Plans - Newser
Best data tools to analyze Boundless Bio Inc. stock [Market Trend Review]Weekly Top Performers Watchlists - Newser
Has Boundless Bio Inc. formed a bullish divergenceDaily Stock Forecast Powered by AI Tools - Newser
Momentum divergence signals in Boundless Bio Inc. chartReal Trader Watchlist with Entry Targets - Newser
What makes Boundless Bio Inc. stock price move sharplyEarly Entry Planner for Swing Candidates - Newser
Why Boundless Bio Inc. stock attracts strong analyst attentionBreakout Stocks with Huge Upside - thegnnews.com
How Boundless Bio Inc. stock performs during market volatilityFree Risk Adjusted Technical Entry Plan - Newser
Forecasting Boundless Bio Inc. price range with options dataSector Rotation and Stock Opportunity Analysis - Newser
Boundless Bio stock price target lowered to $4 at H.C. Wainwright - Investing.com Australia
Boundless Bio: HC Wainwright Maintains Buy Rating, Lowers PT to $4 - AInvest
What’s next for Boundless Bio Inc. stock priceSwing Reversal Forecast Based on Patterns - Newser
Leading vs lagging indicators on Boundless Bio Inc. performanceSummary of Trade Cycles in 5-Year Range - Newser
Will Boundless Bio Inc. rebound enough to break evenFree Growth Based Investment Plan Guidance - Newser
Can Boundless Bio Inc. expand into new marketsHigh Confidence Setup Screener - thegnnews.com
Boundless Bio Inc. stock volume spike explainedBuy Strategy Tracker with Growth Indicators - Newser
Is it too late to sell Boundless Bio Inc.Free Smart Trade Plans With Risk Protection - Newser
Signal strength of Boundless Bio Inc. stock in tech scannersFree Short Term Setup With Predictive Chart - Newser
Real time breakdown of Boundless Bio Inc. stock performanceFree Secure Capital Picks With Upside Potential - Newser
Using portfolio simulators with Boundless Bio Inc. includedPrice Forecast Based on AI Analysis - Newser
Statistical indicators supporting Boundless Bio Inc.’s strengthStock Holding Strategy Long-Term Summary Sheet - Newser
Published on: 2025-08-05 20:14:30 - Newser
Boundless Bio Q2 R&D Expenses Down 17%, Cash to Fund Operations Until H1 2028 - AInvest
Boundless Bio (BOLD) Q2 R&D Drops 17% - Nasdaq
Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights - The Manila Times
Boundless Bio's Strategic Focus on ecDNA-Driven Oncology and Extended Runway: A Biotech Investment for the Long Term - AInvest
What earnings revisions data tells us about Boundless Bio Inc.Free Smart Trend Trading with Weekly Signals - Newser
Is Boundless Bio Inc. stock poised for growthTechnical Screener for High Growth Stocks - Newser
What are the technical indicators suggesting about Boundless Bio Inc.Discover investment plans that deliver results - Jammu Links News
Is a relief rally coming for Boundless Bio Inc. holdersChart Pattern Recognition for Profit Timing - Newser
When is Boundless Bio Inc. stock expected to show significant growthInvest confidently with daily market forecasts - Jammu Links News
What are Boundless Bio Inc. company’s key revenue driversFree Predictions - Jammu Links News
Is Boundless Bio Inc. stock overvalued or undervaluedAccess high-quality stock research instantly - Jammu Links News
What analysts say about Boundless Bio Inc. stockMassive portfolio appreciation - Jammu Links News
How strong is Boundless Bio Inc. company’s balance sheetBreakthrough wealth creation - Jammu Links News
What catalysts could drive Boundless Bio Inc. stock higher in 2025Build a diversified portfolio for stability - Jammu Links News
What are the latest earnings results for Boundless Bio Inc.Stay ahead with advanced stock screening tools - Jammu Links News
Is Boundless Bio Inc. a growth stock or a value stockHigh-performance investment picks - Jammu Links News
Does Boundless Bio Inc. stock perform well during market downturnsUnlock your portfolio’s full growth potential - Jammu Links News
How does Boundless Bio Inc. compare to its industry peersAchieve consistent double-digit growth - Jammu Links News
How does Boundless Bio Inc. generate profit in a changing economyUnstoppable profit momentum - Jammu Links News
What drives Boundless Bio Inc. stock priceMaximize gains with data-driven stock picks - Jammu Links News
Finanzdaten der Boundless Bio Inc-Aktie (BOLD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.91%
3.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):